ESMO 2026

2026 年 10 月 23–27 日 · Madrid · 共 4118 条

KEYNOTE-C93

2 人 · 2 条

本事件热度走势

当前热度 1·可比范围峰值 1（10月26日 13:00）·近 24 小时可比范围变化 –·当前参与者 1

参与者计数1

热度走势

现场

17:30
OncoAlert@OncoAlert
OncoAlert 4Sight 摘要将在 #ESMO26 上展示 KEYNOTE-C93/GOG-3064/ENGOT-en15：一项 3 期、随机、开放标签研究，比较一线 Pembrolizumab 与 Carboplatin + Paclitaxel 治疗错配修复缺陷 (dMMR) 晚期或复发性子宫内膜癌 @GynCancerMD, @MirzaCPH, @FBackesMD, @Josei20444240 🔬 3 期 (n=299)：一线 pembrolizumab 与 carboplatin + paclitaxel 治疗 dMMR 晚期/复发性子宫内膜癌。主要终点：BICR 评估的 PFS 和 OS；中位随访时间 36.5 个月。 ➡️ PFS 中位数 38.2 vs 8.4 个月；HR 0.57 (0.42–0.79) ➡️ OS HR 0.77 (0.52–1.15)；化疗组中发生进展的患者有 85.2% 接受了 PD-(L)1 治疗 ➡️ ≥3 级 TRAEs 18.1% vs 50.7% ✅ 作者：PFS 改善显著且持久，OS 趋势良好；单药 pembrolizumab 可作为该人群的一种选择。#EndometrialCancer 🎙️ Brian Slomovitz 👥 David Cibula · Tayup Simsek · Mansoor Raza Mirza · Beata Maćkowiak-Matejczk · Emma Hudson · Ignacio Romero · Nicoletta Colombo · Jacob Korach · Rutie Yin · Lucy Gilbert · Kosei Hasegawa · Alexandra Tyulyandina · Sally Baron-Hay · Lyndsay Willmott · Floor Backes · Robert Orlowski · Xuan Zhou · Vivek Khemka · Sandro Pignata (4Sight 根据 ESMO 网站公开提供的摘要制作)
同题 KEYNOTE-C93 · 2 人 pembrolizumab paclitaxel GOG-3064 #ENDOMETRIALCANCER106 浏览2 赞4 转发0 回复
12:41
Dr Rishabh Jain@DrRishabhOnco
🚨 38.2 vs 8.4 个月！我们能否在一线 dMMR 子宫内膜癌中 eliminating 化疗？ #ESMO26 LBA12 | KEYNOTE-C93 Pembrolizumab vs Carbo/Paclitaxel： 🔥 PFS：38.2 vs 8.4 个月（HR 0.57） 🔥 ≥3 级 TRAEs：18.1% vs 50.7% 🔥 中位缓解持续时间：NR vs 10.2 个月这是迈向无化疗治疗的重要一步！ OS 数据仍未成熟。 @myesmo @ESMO_open @ASCO @oncoalert
引用@
🚨 ESMO 2026 | TOP 10 GYNAE ONCOLOGY TRIALS TO WATCH! From chemotherapy-free immunotherapy to next-generation ADCs, #ESMO26 could reshape gynaecological oncology! 🔥 My Top 10, by cancer subtype: 🔴 ENDOMETRIAL CANCER TroFuse-005 (LBA11) | Sacituzumab tirumotecan vs physician’s choice in recurrent/advanced disease. KEYNOTE-C93 (LBA12) | Pembrolizumab alone vs chemotherapy in 1L dMMR disease. Can we omit chemotherapy? NRG-GY020 (1239O) | Adjuvant radiotherapy ± pembrolizumab in early-stage dMMR disease. Sacituzumab tirumotecan + pembrolizumab (1259P) | ADC + immunotherapy in post-platinum pMMR disease. 🔵 OVARIAN CANCER BEHOLD-1 (LBA41) | Mocertatug rezetecan, a B7-H4 ADC, in platinum-resistant disease. REJOICE-Ovarian02 (1247RO) | Raludotatug deruxtecan + bevacizumab in platinum-resistant disease. REJOICE-Ovarian01 (1331P) | Updated efficacy and safety of raludotatug deruxtecan. BEHOLD-1 biomarker analysis (1248RO) | Which biomarkers predict response to B7-H4 ADC therapy? 🟣 CERVICAL CANCER CALLA (LBA45) | Tisotumab vedotin + pembrolizumab vs chemotherapy in recurrent/metastatic disease. EMPOWER-Cervical 1 (1250O) | Cemiplimab-based strategies and long-term outcomes. ⭐ My top 3 to watch: KEYNOTE-C93 | TroFuse-005 | BEHOLD-1 Which trial has the greatest potential to change your practice? @ESMO_open @myesmo @ASCO @oncoalert #ESMO26 #GynOnc #Oncology
同题 KEYNOTE-C93 · 2 人 LBA12 pembrolizumab paclitaxel26 浏览0 赞0 转发0 回复